NCT06595108Recruiting
Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 1 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To determine the efficacy and safety of atezolizumab-bevacizumab combination therapy plus stereotactic body radiotherapy(SBRT) in patients with advanced hepatocellular carcinoma, Subjects will start SBRT for one or more primary cancers and/or metastatic lesions and no more than 5 sites within two month before and after the start date of atezolizumab-bevacizumab combination therapy. In this study, it is expected to improve the treatment response rate of atezolizumab-bevacizumab therapy, which is currently first-line chemotherapy but has a low treatment response rate.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 33 (estimated)
- First submitted
- 29 Jul 2024
- Start date
- 28 May 2024
- Primary completion date
- 25 Apr 2027
- Lead sponsor
- Yonsei University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06595108
What you commit to
- Study type: Interventional
- Planned participants: 33
- From 28 May 2024 to the primary completion date, 25 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have a history of malignancy other than hepatocellular carcinoma within the last 5 years (except for malignancies with little risk of metastasis or death, e.g., adequately treated cervical carcinoma in situ, non-melanoma skin cancer, localized prostate cancer, tubular carcinoma in situ, or stage 1 uterine cancer.)
- Subjects with a high probability of untreated gastric or esophageal varices or bleeding
- History of liver transplant surgery
- Autoimmune liver disease
Other
- Brain metastases
- Serious uncontrolled medical comorbidities
Who the study is looking for
- Age 19 to 80 years old
- Liver function Child-Pugh class A
- ECOG 0-1
- Patient clinically or pathologically diagnosed with hepatocellular carcinoma
- Advanced hepatocellular carcinoma that is inoperable
- Satisfies the dose limits for normal organs and lesions of an appropriate size to be included in the scope of radiotherapy.
Age in the registry: 19 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yongin Severance Hospital Coordinator of this site? Confirm its status | Yongin-si | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.